Literature DB >> 30543499

Delayed myonuclear addition, myofiber hypertrophy, and increases in strength with high-frequency low-load blood flow restricted training to volitional failure.

Thomas Bjørnsen1, Mathias Wernbom2,3, Amund Løvstad4, Gøran Paulsen5, Randall F D'Souza6, David Cameron-Smith6,7,8, Alexander Flesche4, Jonny Hisdal9, Sveinung Berntsen1, Truls Raastad4.   

Abstract

The purpose of the present study was to investigate muscle hypertrophy, strength, and myonuclear and satellite cell (SC) responses to high-frequency blood flow-restricted resistance exercise (BFRRE). Thirteen individuals [24 ± 2 yr (mean ± SD), 9 men] completed two 5-day blocks of 7 BFRRE sessions, separated by a 10-day rest period. Four sets of unilateral knee extensions to voluntary failure at 20% of one repetition maximum (1RM) were conducted with partial blood flow restriction (90-100 mmHg). Muscle samples obtained before, during, 3 days, and 10 days after training were analyzed for muscle fiber area (MFA), myonuclei, SC, and mRNA and miRNA expression. Muscle size was measured by ultrasonography and magnetic resonance imaging and strength with 1RM knee extension. With the first block of BFRRE, SC number increased in both fiber types (70%-80%, P < 0.05), whereas type I and II MFA decreased by 6 ± 7% and 15 ± 11% ( P < 0.05), respectively. With the second block of training, muscle size increased by 6%-8%, whereas the number of SCs (type I: 80 ± 63%, type II: 147 ± 95%), myonuclei (type I: 30 ± 24%, type II: 31 ± 28%), and MFA (type I: 19 ± 19%, type II: 11 ± 19%) peaked 10 days after the second block of BFRRE, whereas strength peaked after 20 days of detraining (6 ± 6%, P < 0.05). Pax7- and p21 mRNA expression were elevated during the intervention, whereas myostatin, IGF1R, MyoD, myogenin, cyclinD1 and -D2 mRNA did not change until 3-10 days postintervention. High-frequency low-load BFRRE induced robust increases in SC, myonuclei, and muscle size but modest strength gains. Intriguingly, the responses were delayed and peaked 10-20 days after the training intervention, indicating overreaching. NEW & NOTEWORTHY In line with previous studies, we demonstrate that high-frequency low-load blood flow-restricted resistance exercise (HF-BFRRE) can elicit robust increases in satellite cell and myonuclei numbers, along with gains in muscle size and strength. However, our results also suggest that these processes can be delayed and that with very strenuous HF-BFRRE, there may even be transient muscle fiber atrophy, presumably because of accumulated stress responses. Our findings have implications for the prescription of BFR exercise.

Entities:  

Keywords:  Kaatsu; ischemic exercise; muscle hypertrophy; myogenic stem cells; myonuclei

Mesh:

Substances:

Year:  2018        PMID: 30543499     DOI: 10.1152/japplphysiol.00397.2018

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  9 in total

Review 1.  Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety.

Authors:  Stephen D Patterson; Luke Hughes; Stuart Warmington; Jamie Burr; Brendan R Scott; Johnny Owens; Takashi Abe; Jakob L Nielsen; Cleiton Augusto Libardi; Gilberto Laurentino; Gabriel Rodrigues Neto; Christopher Brandner; Juan Martin-Hernandez; Jeremy Loenneke
Journal:  Front Physiol       Date:  2019-05-15       Impact factor: 4.566

2.  Six Weeks of Low-Load Blood Flow Restricted and High-Load Resistance Exercise Training Produce Similar Increases in Cumulative Myofibrillar Protein Synthesis and Ribosomal Biogenesis in Healthy Males.

Authors:  Peter Sieljacks; Jakob Wang; Thomas Groennebaek; Emil Rindom; Jesper Emil Jakobsgaard; Jon Herskind; Anders Gravholt; Andreas B Møller; Robert V Musci; Frank V de Paoli; Karyn L Hamilton; Benjamin F Miller; Kristian Vissing
Journal:  Front Physiol       Date:  2019-05-29       Impact factor: 4.566

Review 3.  The Evolution of Blood Flow Restricted Exercise.

Authors:  Eduardo D S Freitas; Murat Karabulut; Michael G Bemben
Journal:  Front Physiol       Date:  2021-12-02       Impact factor: 4.566

4.  Acute and Chronic Bone Marker and Endocrine Responses to Resistance Exercise With and Without Blood Flow Restriction in Young Men.

Authors:  Debra A Bemben; Vanessa D Sherk; Samuel R Buchanan; SoJung Kim; Kyle Sherk; Michael G Bemben
Journal:  Front Physiol       Date:  2022-03-17       Impact factor: 4.566

5.  Blood Flow Restriction Therapy and Its Use for Rehabilitation and Return to Sport: Physiology, Application, and Guidelines for Implementation.

Authors:  Daniel J Cognetti; Andrew J Sheean; Johnny G Owens
Journal:  Arthrosc Sports Med Rehabil       Date:  2022-01-28

Review 6.  An Evidence-Based Narrative Review of Mechanisms of Resistance Exercise-Induced Human Skeletal Muscle Hypertrophy.

Authors:  Changhyun Lim; Everson A Nunes; Brad S Currier; Jonathan C McLeod; Aaron C Q Thomas; Stuart M Phillips
Journal:  Med Sci Sports Exerc       Date:  2022-04-06

Review 7.  Role of macrophages during skeletal muscle regeneration and hypertrophy-Implications for immunomodulatory strategies.

Authors:  Clara Bernard; Aliki Zavoriti; Quentin Pucelle; Bénédicte Chazaud; Julien Gondin
Journal:  Physiol Rep       Date:  2022-10

8.  Commentary: Can Blood Flow Restricted Exercise Cause Muscle Damage? Commentary on Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety.

Authors:  Mathias Wernbom; Brad J Schoenfeld; Gøran Paulsen; Thomas Bjørnsen; Kristoffer T Cumming; Per Aagaard; Brian C Clark; Truls Raastad
Journal:  Front Physiol       Date:  2020-03-20       Impact factor: 4.566

9.  Response: Commentary: Can Blood Flow Restricted Exercise Cause Muscle Damage? Commentary on Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety.

Authors:  Jamie F Burr; Luke Hughes; Stuart Warmington; Brendan R Scott; Johnny Owens; Takashi Abe; Jakob L Nielsen; Cleiton Augusto Libardi; Gilberto Laurentino; Gabriel Rodrigues Neto; Christopher Brandner; Juan Martin-Hernandez; Jeremy Loenneke; Stephen D Patterson
Journal:  Front Physiol       Date:  2020-10-30       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.